State Medical and Pharmaceutical University
Chisinau, Chisinau | Moldova, Republic of
Main Specialties: Allergy & Immunology, Pediatric Pulmonology, Pediatrics
Additional Specialties: Pediatrie
Date of birth 01 January 1961
Work address Department of Paediatrics
State Medical and Pharmaceutical University “Nicolae Testemitanu”
165, Stefan cel Mare bd., MD 2004
E-mail email@example.com, firstname.lastname@example.org
1989-2016 – State University of Medicine and Pharmacy “Nicolae Testemitanu”
MD, PhD, Professor of Pediatrics, Department of Pediatrics, Chair
of the Clinic of Pneumology
1978-1984 – State University of Medicine and Pharmacy “Nicolae Testemitanu”,Department of Pediatrics
1984-1986 – State University Medicine and Pharmacy “Nicolae Testemitanu”, Clinic Residency
1986 – 1989 – State University of Medicine and Pharmacy “N. Testemitanu”, PhD Studies
1988-1990 – The Institute of Pediatrics, Russian Academy of Medical Sciences PhD Studies
1999 – University of Medicine and Pharmacy, Iasi, Romania
2001 – Medical University of Virginia, Norfolk, USA
2007 – Medical University of Toulouse, France (pulmonology, allergology, cystic fibrosis)
2012 – University Hospital, Southampton, UK (pulmonology, cystic fibrosis)
2013 – University Clinic Charite, Berlin, Germany (pulmonology, allergology, cystic fibrosis)
Certifications, Professional Membership
European Respiratory Society, 2004-2016
European Academy of Allergy and Clinical Immunology, 2006-2016
European Society of Cystic Fibrosis, 2008-2016
European Academy of Pediatrics, 2007-2016
Reporting on national and international scientific conferences
Pneumology, allergic disorders, immunology, cystic fibrosis, pediatrics scientific congress ERS, EAACI, SFAIC, Excellence in pediatric, conferences ECFS:
Austria (2004, 2007, 2009,2016), Germany (2008, 2012)
France (2007, 2008, 2011), Belgium (2015)
UK (2010), Denmark (2006), Ireland (2012)
Netherlands (2011, 2015), Switzerland (2012)
Italia (2009, 2013), Spain (2008, 2014), Greece (2007)
Romania (1996, 2001, 2008), Russia (1997, 2007, 2009, 2011)
Turkey (2005, 2007)
Publications – 560 Monographs – 4, textbooks – 4, guides – 4, compendium – 7
Publications (articles, abstracts) in national and international medical journals –
- McCormick J, Mehta G, Olesen HV, Viviani L, Macek M, Mehta A.,..,Sciuca S... Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 375 (9719):1007-1013, 2010 doi:10.1016/S0140-6736(09)62161-9 (IF 33,633)
- Mehta G, Macek M Jr, Mehta A.,.. Sciuca S…. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. Journal of Cystis Fibrosis, 2010, 9 (Suppl 2), 5-21. doi:10.1016/j.jcf.2010.08.0 (IF 2,84)
- ?ciuca S. Essential in the pneumology of the child, Chi?in?u, Moldova, 2007, 272 p.
- ?ciuca S.,Turcu O.,Neam?u L. Essential in the immunology of the child. Chi?in?u, 2009, 400p.
- S. Sciuca, R. Eremciuc, L. Pinzaru, D. Rotaru, E. Oineagra: PO-0761 Clinical And Evolutive Peculiarities Of The Bronchopulmonary Dysplasia And Wilson-mikity Syndrome In Premature Children. Archives of Disease in Childhood 10/2014; 99 (Suppl 2). DOI:10.1136/archdischild-2014-307384.1400
- ?ciuca S., Turcu O. Cough induced migraine in a patient with cystic fibrosis. In: Revista Român? de Pediatrie. România, 2011, vol. LX, nr.1, p. 86-88
International projects and awards
• Project MRDA (Moldovan Research and Development Association), U.S. Civilian Research and Development Foundation (CRDF) SUA NB2–3028 “Development program for evaluation in assessment of indoor air” 2002-2003
• Project UNICEF, Moldova – project manager „Education of children with asthma” 2004-2006
• Travel Grants MRDA-CRDF (PRDS-1211) 25 th Internat.Congress of Pediatrics, Greece, Athena, 2007
• Golden Grant for the participation “Turkish Thoracic Society Annual Congress” 2005, 2007
• Clinical Study CRO-09-100 Pharmacokinetic study of BRAMITOB® administered for inhalation by PARI eFLOW® rapid electronic nebulizer versus PARI LC® PLUS nebulizer coupled with the PARI TurboBOY N® compressor in cystic fibrosis patients infected with Pseudomonas aeruginosa, 2011, Principal Investigator
• Study Clinical and Functional Translation of CFTR (CFTR2) – contributors, MD 2011-2015. http://cftr2.org/contributors.php; http://cftr2.org/about_cftr
• Project European Cystic Fibrosis Society Patient Registry (ECFSPR). National coordonator, 2011-2015. https://www.ecfs.eu/projects/ecfs-patient-registry/steering-committee
• Moldova-France-Germany Project– collaboration programme in cystic fibrosis, “Pediatres du monde”, “Pharmaciens sans frontiers”, 2004-2014
• Moldova-Germany Project – Programme in cystic fibrosis, “Mukoviszidose e.V.”, 2010-2014
• Moldova-United Kingdom Program in cystic fibrosis,”Child Health International”,2010-2012
PhD student • 7
Primary Affiliation: State Medical and Pharmaceutical University - Chisinau, Chisinau , Moldova, Republic of
J Clin Immunol 2019 05 17;39(4):363-369. Epub 2019 May 17.
Department of Dermatology, Venerology and Dermatooncology, Semmelweis University Budapest, Budapest, Hungary.
Download full-text PDF
J Clin Immunol. 2019 May; 39(4):363-369
J Clin Immunol.
Over the past 15 years, remarkable progress has been made of clinical care, laboratory diagnosis, and in particular, genetics in the field of primary immunodeficiency diseases (PIDs) . This progress resulted mostly from a better understanding of the relationship between genotype and phenotype variability in patients with “normal” immunity and in those with increased susceptibility to infection, inflammatory and autoimmune disorders, allergy, and cancer . The wondrous unraveling of the human genome sequence by virtue of the human genome project from 1991 to 2004, and later on by other international collaborative projects like HapMap, 1000 genome project, and ENCODE, has opened the way to the rapid development of the field . Introduction of new generation sequencing (NGS), whole genome sequencing (WGS), and whole exome sequencing (WES) in 2010 revolutionized the diagnosis and research of PIDs leading to the discovery of hundreds of novel inborn errors of immunity . Progress...
Eur Respir J 2015 Jul 18;46(1):133-41. Epub 2015 Mar 18.
CF and Airways Microbiology Group, Queen's University Belfast, Belfast, UK Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
Download full-text PDF
Journal of Cystic Fibrosis 9 (2010) S5–S21
Journal of Cystic Fibrosis
Methods: We applied methods that had successfully created country-specific registries inviting wide participation to obtain consent and collate demographic and CFTR genotype data.Results: Among 29,095 patients, a widely different country-specific prevalence of childhood CF exists that cannot be explained by differential population frequency of mutant-CFTR or case under-ascertainment with a significant paucity of the homozygous p.Phe508del genotype that presents in childhood in N90% of cases.Conclusions: Excess premature childhood CF mortality may still occur. The better resourced Western Europe now has a ~5% mortality for childhood CF, which is not apparent in many of the European countries reported here. In addition, a female survival disadvantage exists. Thereasons require further investigation. We showcase the value of simple data collection in one rare disease, which might interest those managing rare diseases across the globe.
Lancet 2010 Mar;375(9719):1007-13
Centre for Academic Clinical Practice, Division of Clinical Population Science and Education, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK.
Background: Country-specific patients' registries are rarely used to make international comparisons because of protocol discrepancies in data collation. We present data from a European cystic fibrosis registry that is dedicated to collection of demographic data, and assess whether the resources available in countries with and without European Union (EU) membership affects care and survival of patients.
Methods: Data for demographic indicators-age, age at diagnosis, sex, and genotype-for patients with cystic fibrosis from 35 European countries were combined, and used to establish the differences in demographic indicators between EU and non-EU countries. EU membership status in 2003 was used to divide countries. We modelled demographic indicators of EU countries on non-EU countries to estimate the size of the cystic fibrosis population if non-EU countries had had the same resources available for patients as did EU countries.
Findings: Data were gathered for 29 025 patients, who had a median age of 16.3 years (IQR 8.9-24.8), with a difference of 4.9 years (95% CI 4.4-5.1; p<0.0001) between EU (median 17.0 years, IQR 9.5-25.6) and non-EU countries (12.1 years, 6.0-19.2). The proportion of patients older than 40 years was higher in EU countries (1205 [5%]) than in non-EU countries (76 [2%]), with an odds ratio of 2.4 (95% CI 1.9-3.0, p<0.0001). We estimated that the cystic fibrosis population in non-EU countries would increase by 84% if patients had a demographic profile comparable to that of patients in EU countries.
Interpretation: Future studies need to establish the reasons for the lower proportion of patients with cystic fibrosis in non-EU countries than in EU countries, such as underdiagnosis and premature childhood mortality.
Funding: European Community's Sixth Framework Programme for Research, and Czech Ministry of Health.
Download full-text PDF